Despite increasing clinical awareness, the full spectrum of SMARCA4-altered cancers remains incompletely defined, and therapeutic guidelines are lacking due to the rarity of reported cases and the absence of prospective clinical trials [7]. Here, SMARCA4 is linked to cancer.